On October 10, 2019, the launch meeting of the new autologous CAR-T clinical research project co-operated by Jiangsu Provincial People's Hospital and Shanghai Longyao Biotechnology Co., Ltd. was grandly held in Jiangsu Provincial People's Hospital. Relevant personnel from the Department of Hematology, Clinical Research Operation Management Office of Jiangsu Provincial People's Hospital and Shanghai Longyao Biotechnology attended the meeting.
The meeting was presided over by Wang Xiuqin, director of the Clinical Research Operation Management Office of Jiangsu Provincial People's Hospital , and Li Jianyong, director of the Department of Hematology, delivered an important speech. Director Li Jianyong said that the Department of Hematology of Jiangsu Provincial People's Hospital has done a lot of exploration in establishing a clinical system of CAR-T in the early stage, and the experience is relatively mature. Ye Shengqin, President of Shanghai Longyao Biotechnology, also made a warm speech, hoping to establish a domestic and international brand of CAR-T technology through the cooperation between the two parties.
At the same time, Fan Lei , director of the Department of Hematology of Jiangsu Provincial People's Hospital , gave a detailed introduction to the new autologous CAR-T technology route, technical advantages, treatment plan, efficacy evaluation and follow-up plans. Experts participating in the meeting had a lively and fruitful discussion on the technical plan and development route of the project.
Leaders and experts at the meeting expressed their recognition and confidence in the new autologous CAR-T project of Shanghai Longyao Biotechnology. Both parties hope to further establish exploratory research in other fields of cell therapy based on the establishment of cooperation on the new autologous CAR-T clinical research standard system. Collaboration in clinical research.
On-site discussion at the kick-off meeting
Jiangsu Provincial People's Hospital is a national drug clinical trial institution (GCP base), which has advantages in clinical research, facility services, personnel training, etc. Hematology is a key clinical specialty in Jiangsu Province, and a blood disease base of the National Drug Clinical Research Institute , which has an important influence. force .